Early continuous veno-venous haemofiltration in the management of severe acute pancreatitis complicated with intra-abdominal hypertension: retrospective review of 10 years' experience by Guntars Pupelis et al.
RESEARCH Open Access
Early continuous veno-venous haemofiltration in
the management of severe acute pancreatitis
complicated with intra-abdominal hypertension:
retrospective review of 10 years’ experience
Guntars Pupelis*, Haralds Plaudis, Kaspars Zeiza, Nadezda Drozdova, Maksims Mukans, Ita Kazaka
Abstract
Background: Conservative treatment of patients with severe acute pancreatitis (SAP) may be associated with
development of intra-abdominal hypertension (IAH), deterioration of visceral perfusion and increased risk of
multiple organ dysfunction. Fluid balance is essential for maintenance of adequate organ perfusion and control of
the third space. Timely application of continuous veno-venous haemofiltration (CVVH) may help in balancing fluid
replacement and removal of cytokines from the blood and tissue compartments. The aim of the present study was
to determine whether CVVH can be recommended as a constituent of conservative treatment in patients with SAP
who suffer IAH.
Methods: A retrospective analysis of 10 years’ experience with low-flow CVVH application in patients with SAP
who develop IAH was. In all patients, measurement of the intra-abdominal pressure (IAP) was done indirectly
through the urinary bladder. Sequential organ failure assessment (SOFA) score was calculated for severity
assessment, and necrotizing forms were verified by contrast-enhanced computed tomography. Dynamics of IAP
were analysed in parallel with signs of systemic inflammation, dynamics of C-reactive protein and cumulative fluid
balance. All variables, complication rate and outcomes were analysed in the whole group and in patients with IAH
(CVVH and no-CVVH groups).
Results: From the total of 130 patients, 75 were treated with application of CVVH and 55 without CVVH. Late
hospitalization was associated with application of CVVH. Infection was observed in 28.5% of cases regardless of the
type of treatment received, with a similar necessity for surgical intervention. IAH was observed in 68.5% of patients,
and they had significantly higher SOFA scores compared to patients with normal IAP. CVVH treatment resulted in
negative cumulative fluid balance starting from day 5 in patients with IAH, whereas without this treatment, fluid
balance remained increasingly positive after a week. Finally, application of CVVH resulted in a lower infection rate
and shorter hospital stay, 26.7% vs. 37.9%, and a median of 32 (interquartile range (IQR) = 60 to 12) days vs. 24
(IQR = 34 to 4) days, p = 0.05, comparing CVVH vs. no-CVVH group. Mortality rate reached 11.7% in the CVVH
group and 13.8% in the no-CVVH group.
Conclusions: Early application of CVVH facilitates negative fluid balance and reduction of IAH in patients with SAP;
it is not associated with increased infection or mortality rate and may reduce hospital stay.
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Background
Severe acute pancreatitis (SAP) manifests itself with local
inflammation, which involves the pancreas and surround-
ing tissue, and systemic inflammation with characteristic
systemic increase of vascular permeability. Exudation with
inflammatory fluid accumulations in intra-abdominal, ret-
roperitoneal and pleural cavities is characteristic of SAP
(grade E according to the Balthazar computed tomography
severity index) [1]. Retroperitoneal and intraperitoneal dis-
tribution of inflammatory fluid and visceral oedema may
cause elevation of intra-abdominal pressure (IAP) with
resultant intra-abdominal hypertension (IAH) [2]. Pro-
longed IAH affects visceral perfusion and organ function,
leading to the development of multiple organ dysfunction
(MODS) and impairment of bowel barrier function and
thus increasing the risk of bacterial translocation and sep-
tic complications [3]. In the early phase, severity of the
clinical course depends on the magnitude of systemic
inflammation and anti-inflammatory capacity of the
immune response [4]. Disbalanced inflammatory response
facilitates invasion of infection, leading to poor prognosis
with 30% to 50% mortality [5]. Fast reduction of inflamma-
tory fluid accumulation and decrease of visceral oedema
improve early treatment prognosis considerably, while late
prognosis generally depends on the presence of infection
[6]. Management of IAH and the abdominal compartment
syndrome (ACS) includes conservative measures; however,
when they fail, surgical treatment is the only remaining
option. In the line of conservative treatment modalities,
continuous veno-venous haemofiltration (CVVH) is posi-
tioned mostly as an option for treatment of renal dysfunc-
tion with relatively low C grade of evidence [7]. It is
proved that application of CVVH facilitates removal of
cytokines and biologically active substances from the
blood and also from the extravascular compartment, redu-
cing fluid sequestration in the third space [8]. This retro-
spective study was aimed to summarize our 10 years of
experience in the clinical application of CVVH as well as
to determine the incidence of IAH in SAP patients, assess
the impact of CVVH on IAP and evaluate available data




Medical histories of SAP patients who were admitted to
Riga East Clinical University Hospital ‘Gailezers’ during
the period from January 2000 to June 2010 were analysed
retrospectively. SAP was diagnosed according to the
Atlanta criteria based on the clinical course of the disease,
a threefold increase in lipase activity in plasma and one of
the following criteria: systemic inflammation and/or signs
of organ dysfunction, and acute physiology and chronic
health evaluation (APACHE) II score >8 [9]. Severity
assessment was done by calculation of sequential organ
failure assessment (SOFA) score for recognition of organ
dysfunction [10]. Necrotizing forms were verified by con-
trast-enhanced computed tomography (CECT) scan and
elevated C-reactive protein (CRP) level above 250 mg/L.
Abdominal pressure measurement
IAP was measured and recorded at least twice daily
indirectly through the urinary bladder after instillation of
a 50-mL sterile saline solution; we used the symphysis as
the reference point before the latest recommendations of
the World Society of the Abdominal Compartment
Syndrome (WSACS) were published in November 2006
[11]. Since April 2007, we followed WSACS guidelines
which recommend supine position of the patient, instilla-
tion of a 20-mL sterile saline solution and the linea axil-
laris media and crista iliaca cross point as the zero point.
The results were expressed in millimetres of mercury
(mmHg). Measurement techniques did not demonstrate
significant differences in measurement results before and
after April 2007.
Definitions
IAH was defined by a sustained or repeated pathological
elevation in IAP ≥ 12 mmHg. ACS was diagnosed when
sustained increase of the IAP > 20 mmHg and one new
organ dysfunction were detected [11].
Treatment protocol
All patients were treated according to standardized treat-
ment protocol, and the only difference was whether CVVH
was applied during the treatment course. The main indica-
tions for CVVH were the following: evidence of increased
exudation due to progression of systemic inflammation,
and formation of multiple fluid collections accompanied by
deterioration of respiratory and kidney functions, despite
the 24- to 48-h intensive treatment provided according to
the approved treatment protocol of SAP. Development of
MODS and sustained increase of IAP ≥12 mmHg in these
patients was a strong indicator for commencement of
CVVH. The procedure was performed using Diapact
CRRT B.Braun Co (Melsungen, Germany) or Fresenius
Medical Care Multifiltrate machines (Bad Homburg,
Germany). Synthetic high-volume membrane filters with a
surface area of 1.5 to 2.2 m2 were used and changed every
24 h or when filter blocking occurred. Vascular access was
obtained by a double- or triple-lumen catheter using the
femoral or jugular vein. Anticoagulation was provided with
non-fractioned heparin, adjusting the dosage according to
the value of activated partial thromboplastin time in the
plasma. The procedure was performed with a low dose of
heparin or without it when possible. The substitution fluid
infusion rate was 1,000 to 1,460 mL/h in a pre-diluted or
post-diluted manner, comprising 24 to 35 L of the total
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substitute in 24 h. The blood flow rate was 50 to 200 mL/
min. Ultrafiltration rate was adjusted according to the diur-
esis and fluid balance.
The conservative treatment strategy was identical in
both groups and included isovolemic haemodilution with
early and adequate colloid infusion, oxygen supply, stimu-
lation of kidney function, other organ support and intrave-
nous antibacterial prophylaxis with fluoroquinolones 400
mg twice daily and metronidazole 500 mg three times a
day or imipenem/cilastatin monotherapy 500/500 mg four
times daily. On routine basis, within 48 to 72 h from
admission, we commenced low-volume enteral nutrition
with iso-osmolar, whole protein low-fat enteral feeding
formulas, which helped in the stimulation of the gut and
recovery of the gut transit function. Indications for early
surgical intervention were obscure diagnosis or failure to
control sustained increase of the IAP with conservative
treatment. Late surgical interventions were done in cases
when infection of pancreatic/peripancreatic necrosis com-
plicated the clinical course.
Follow-up and outcome prediction
All patients were assessed regarding the severity and clin-
ical course of the disease. Complications and outcomes
were analysed comparing treatment results in patients
who underwent CVVH and those who did not undergo
CVVH. For patients with IAH, a separate analysis of
severity, complication rate and outcomes was performed,
grouping patients with IAH in CVVH and no-CVVH
groups.
Measurements of IAP were analysed in parallel with
the assessment of the degree of organ dysfunction using
SOFA score, CRP and activity of serum lipase.
Our major endpoint was hospital mortality. Secondary
endpoints were incidence of septic complications, length
of stay in intensive care unit (ICU) and overall hospital
stay.
Statistics
Data are presented as mean with standard deviation when
normally distributed and as median with interquartile
range (IQR) in case of non-normal distribution. Analysis
was performed with the Student’s t test, Mann-Whitney
test or the likelihood ratio test whenever appropriate.
Categorical data were compared and assessed by Chi-
square test, and significance was verified by Fisher’s exact
test. Univariate analysis was performed separately on
patients with IAH, comparing patients without IAH, as
well as between the CVVH group and the no-CVVH
group. Additionally univariate analysis was performed to
compare data in survivors vs. non-survivors on the whole
patient group - to see whether IAP is a predictor for
outcome.
Stepwise multiple logistic regression analysis was used
to find an independent predictor of mortality and to ver-
ify its significance. Multiple logistic regression analysis
was done to identify predictive factors for IAH. To ascer-
tain the cut-off values and verify the significance of the
predicting value of IAP and abdominal perfusion pres-
sure (APP), receiver operating characteristic (ROC) curve
analysis was performed with calculation of the area under
the ROC curve. Statistical analysis was done using SPSS
version 17.0 (IBM Corporation, Chicago, IL, USA).
Results
Demographics, incidence of IAH, organ failure and
complication rate in whole group
The mean age of patients was 47.6 years, male patients
dominated, and IAH was more often found in males. The
overall incidence of IAH was 68.5%; however, incidence
of initial organ failure was the same among patients with
normal IAP compared to patients who developed IAH. It
became evident that patients with IAH were hospitalized
significantly later and underwent CVVH more often
(Table 1). The SOFA score was significantly increased in
patients with IAH on day 4 after admission and com-
mencement of therapy. This elevation was observed for
the next 2 consecutive days, and then SOFA score
decreased in both groups (Figure 1). In total, 75 patients
underwent CVVH and 55 patients were treated without
application of CVVH. The overall incidence of infection
was 28.5% regardless of the type of treatment with similar
necessity for surgical intervention in patients with normal
IAP and those who developed IAH (Table 1).
Influence of CVVH treatment on whole group
Just like in the whole group, males dominated in the
group of patients who underwent CVVH; they were
admitted to the hospital significantly later in the course
of the disease and had significantly higher IAP measure-
ments on admission, with more frequent development of
necrotizing forms compared to patients who did not
undergo CVVH. Commencement of the procedure was
started within the first 48 h after admission with a med-
ian duration of 72 (IQR = 119 to 44.8) h in 78% of
patients. Development of metabolic acidosis and a higher
rate of pulmonary complications were significant among
patients who underwent CVVH; however, infection rate
and the need for surgical treatment were the same com-
pared to patients treated without CVVH (Table 2).
Management of patients with IAH
For further assessment, patients with IAH were divided in
CVVH group and no-CVVH group. MODS complicated
the clinical course in both groups equally. In the beginning
of the treatment, 65% of patients from CVVH group had
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signs of renal dysfunction. The mean creatinine value
before the start of CVVH was 162.7 ± 124.8 μmol/L; 26
patients (43.3%) in this group had oliguria, while only 6
(20.7%) oliguric patients were treated without CVVH (p =
not significant (NS)). Radiologic evidence of pleural effu-
sion and pneumonia was typical for patients with multiple
inflammatory fluid collections; most of them underwent
CVVH. During the first week of treatment, development
of pulmonary complications and metabolic acidosis were
observed significantly more often in the CVVH group,
correlating with the significantly higher rate of necrotizing
forms. ACS developed approximately in one third of
patients, without significant differences between the
groups (Table 3). Vasopressor support was needed for
eight patients (13.3%) in the CVVH group and for two
patients (6.9%) in the no-CVVH group (p = NS). Ventila-
tory support during the conservative treatment period was
used in 15 patients (25%) from the CVVH group and in
2 (6.9%) patients from the no-CVVH group (p = 0.048).
Mean values of cumulative fluid balance in CVVH group
were close to 0 on day 4 after commencement of conser-
vative treatment and significantly different compared to
no-CVVH group. Starting from day 5, it became negative
(Figure 2).
CVVH treatment influenced the dynamics of IAP posi-
tively. After commencement of conservative therapy, a
similar elevation of the IAP was observed in both groups
on day 1. On day 2, IAP reached 19.6 ± 7.1 mmHg
in patients who later underwent CVVH vs. 16.3 ±
5.5 mmHg in the no-CVVH group (p = 0.05). Application
of CVVH resulted in faster decrease of IAP during the
first phase of the disease when IAP reached 10.6 ± 3.9
mmHg within 2 weeks, while the mean IAP in patients
treated without CVVH was still elevated at 12.9 ± 4.1
mmHg (Figures 3 and 4).
Systemic inflammation and infection rate
On admission, CRP, the marker of systemic inflammation,
was significantly higher in the CVVH group with 227.9 ±
128.8 mg/L compared to 97.7 ± 62.8 mg/L in the no-
CVVH group (p = 0.02). The difference increased on the
third day after commencement of the therapy reaching
324.5 ± 179.3 mg/L vs. 153.7 ± 91.6 mg/L (p = 0.044),
respectively, and normalized in both groups during a
2-week period. CVVH application time correlated with a
faster decrease of CRP (Figure 5). Decrease of lipase activ-
ity in the serum was rapid in both groups, dropping within
the first 48 h from 2,493.2 ± 1247.6 U/L to 589.6 ± 346.4
U/L and from 2,074 ± 971.3 U/L to 426.4 ± 297.8 U/L
similarly in the CVVH group and the no-CVVH group.
The conservative therapy with application of CVVH
resulted in a lower infection rate, and consequently, surgi-
cal treatment was necessary in only 26.7% of patients from
this group compared to 34.5% of patients in the no-CVVH
group (Table 3).
Main outcomes
To assess the main outcomes, we took the following steps.
First of all, we assessed main outcomes among all patients
and did not discover significant differences in regard to
CVVH application. However, the overall hospital stay was
significantly longer in patients with IAH, while ICU stay
was not different compared to patients with normal IAP.
Analysis according to the likelihood test revealed signifi-
cant difference in mortality. Patients with IAH had a
higher death rate compared to patients with normal IAP,
but Fisher’s exact test did not reveal the difference. We
then assessed outcomes only in patients with IAH and
discovered that application of CVVH resulted in a shorter
hospital stay compared to patients with IAH who were
treated without CVVH (Table 4). Application of univariate
analysis revealed that non-survivors were operated more
often (Table 5). Logistic regression analysis found that
IAH is an independent predictor of mortality (p = 0.043),
while renal dysfunction (p = 0.011) and pleural effusion (p
< 0.001) are independent predictors of IAH. Finally, we
performed ROC analysis to look for thresholds of IAP and
APP that are predictive for mortality. Analysis showed
Table 1 Demographics, incidence of IAH, organ failure and complication rate in whole group
Total group N = 130 IAH N = 89 no IAH N = 41 p value
Age, years (range) 47.6 ± 15.4 (19 to 84) 47.1 ± 14.6 (21 to 84) 48.6 ± 17.0 (19 to 81) NS
Male, n (%) 95 (73.1%) 70 (78.7%) 25 (61.0%) 0.035
Time from the first symptoms to hospitalization, median hours (IQR) 20 (48 to 4) 24 (48 to 5.8) 13 (22.5 to 0.5) 0.001
APACHE II at admission, points 7.6 ± 4.5 7.8 ± 4.7 7.1 ± 4.0 NS
IAP on admission, mmHg 13 ± 3.8 14.9 ± 3.8 10.5 ± 1.7 0.001
SOFA on admission, points 2.3 ± 2.1 2.3 ± 2.1 2.4 ± 1.9 NS
Necrotizing SAP, n (%) 89 (68.5%) 65 (73.0%) 24 (58.5%) NS
MODS, n (%) 122 (93.9%) 84 (94.4%) 38 (92.7%) NS
Underwent CVVH, n (%) 75 (57.7%) 60 (67.4%) 15 (36.6%) 0.001
Pancreatic/peripancreatic infection, n (%) 37 (28.5%) 27 (30.3%) 10 (24.4%) NS
Surgical intervention, n (%) 36 (27.7%) 26 (29.2%) 10 (24.4%) NS
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that APP is not a suitable predictor of mortality; however,
IAP is a significant predictor of mortality with high sensi-
tivity at the level of 17.09 mm Hg (Figures 6 and 7).
Discussion
The aim of this retrospective study was to summarize our
experience in the clinical application of CVVH in SAP
patients who develop IAH. Our data demonstrate that
male patients in their late 40s who were hospitalised after
a 24-h period from the appearance of the first symptoms
frequently had increased IAP on admission. Partially, it
can be explained by the high number of alcohol abusers
among these patients, with their often careless attitude to



















Figure 1 Dynamics of SOFA score. (A) Patients with IAH and normal IAP in whole group. Significant difference on day 4 (p = 0.04), day 5
(p = 0.01) and day 6 (p = 0.04). (B) Survivors and non-survivors in whole group. Significant difference on day 3 (p = 0.004), day 4 (p = 0.001),
day 5 (p = 0.0006) and day 6 (p = 0.0008).
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was 68.5%, demonstrating clinical significance of this
pathophysiologic phenomenon. However, these results
show indirectly that, in majority of the cases, the increase
of the IAP was observed after commencement of the
conservative treatment that included balanced fluid
replacement therapy and organ support for improvement
of tissue perfusion [7]. Reaching the optimal fluid balance
is quite a challenging task, and failure of the initial
Table 2 Impact of CVVH treatment on whole group
Treatment
CVVH n = 75 no CVVH n = 55 p value
Demographics Age, years 44.7 ± 13.9 51.5 ± 16.6 NS
Male, n (%) 65 (86.7%) 31 (56.4%)
Time from the first symptoms to hospitalization, median hours (IQR) 16 (26.8 to 3.8) 19.5 (48 to 11.5) NS
APACHE II at admission, points 7.8 ± 4.1 7.5 ± 4.8 NS
IAP on admission, mmHg 14.2 ± 4.0 11.8 ± 3.0 0.048
SOFA on admission, points 2.4 ± 2.2 2.2 ± 1.9 NS
Necrotizing SAP, n (%) 62 (82.7%) 28 (50.9%) <0.001
MODS, n (%) 70 (93.3%) 53 (96.3%) NS
Organ dysfunctions Renal dysfunction, n (%) 32 (42.7%) 15 (27.3%) NS
Pulmonary dysfunction, n (%) 12 (16.0%) 5 (9.1%) NS
Liver dysfunction, n (%) 12 (16.0%) 6 (10.9%) NS
Cardiovascular, n (%) 6 (8%) 3 (5.5%) NS
Hematologic, n (%) 5 (6.7%) 4 (7.2%) NS
Neurologic, n (%) 15 (20%) 6 (10.9%) NS
Complications Metabolic acidosis, n (%) 24 (32%) 7 (12.7%) 0.013
Pleural effusion, n (%) 47 (62.7%) 14 (25.5%) <0.001
Pneumonia, n (%) 31 (41.3%) 5 (9.1%) <0.001
Atelectasis, n (%) 11 (14.7%) 2 (3.6%) 0.043
Pancreatic/peripancreatic infection, n (%) 21 (28%) 16 (29.1%) NS
Surgical intervention, n (%) 21 (28%) 15 (27.3%) NS
Table 3 Application of CVVH in patients with IAH
CVVH N = 60 No CVVH N = 29 p
Demographics Age, years 45.1 ± 13.4 51.3 ± 16.4 NS
Male, n (%) 52 (86.7%) 18 (62.1%)
Time from the first symptom to hospitalization, median hours (IQR) 32 (60 to 12) 24 (34 to 4) NS
APACHE II at admission, points 7.9 ± 5.1 7.2 ± 4.2 NS
IAP on admission, mmHg 15.4 ± 3.7 14.5 ± 3.7 NS
SOFA on admission, points 2.4 ± 2.2 2.0 ± 1.9 NS
Necrotizing SAP, n (%) 49 (81.7%) 16 (55.2%) 0.01
MODS, n (%) 58 (96.7%) 26% (89.7) NS
ACS, n (%) 23 (38.3%) 10 (34.5%) NS
Organ dysfunctions Renal, n (%) 27 (45%) 8 (27.6%) NS
Pulmonary, n (%) 11 (18.3%) 3 (10.3%) NS
Liver, n (%) 6 (10%) 3 (10.3%) NS
Cardiovascular, n (%) 5 (8.3%) 2 (6.9%) NS
Hematologic, n (%) 4 (6.7%) 3 (10.3%) NS
Neurologic, n (%) 15 (25%) 4 (13.8%) NS
Complications Metabolic acidosis, n (%) 15 (25%) 2 (6.9%) 0.05
Pleural effusion, n (%) 40 (66.7%) 11 (37.9%) 0.01
Pneumonia, n (%) 28 (46.7%) 4 (13.8%) 0.002
Atelectasis, n (%) 8 (13.3%) 2 (6.9%) NS
Pancreatic/peripancreatic infection, n (%) 16 (26.7%) 11 (37.9%) NS
Surgical intervention, n (%) 16 (26.7%) 10 (34.5%) NS
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treatment can lead to development of IAH, progressive
deterioration of tissue perfusion and organ dysfunction
[12]. Current knowledge about the treatment of IAH and
ACS is somewhat controversial; while CVVH is men-
tioned as a treatment modality, it is by far not the leading
one [13]. Preventive treatment is the most effective
A  
B
Figure 2 Dynamics of daily and cumulative fluid balance. (A) Daily fluid balance. Significant difference on day 3 (p = 0.02), day 4 (p = 0.007) and
day 5 (p = 0.007). (B) Cumulative fluid balance. Significant difference on day 2 (p = 0.05), day 3 (p = 0.001), day 4 (p = 0.0008), day 5 (p = 0.0008), day 6
(p = 0.0006) and day 7 (p = 0.0006).
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approach; however, a number of publications have given
emphasis to the treatment of ACS, making analysis of
how to prevent IAH less prominent.
Our strategy was based on evaluation of the 24-h con-
servative treatment response. Negative dynamics of sys-
temic inflammation, increase of the IAP and deterioration
of the organ function were critical signs for reconsidera-
tion of our therapeutic strategy and application of CVVH.
More than half of our patients underwent CVVH within
the first 48 h from admission. Patients with IAH were the
first candidates for the procedure because 65% of them
had signs of renal failure with significant incidence of
metabolic acidosis. Majority of them were hospitalized late
and had necrotizing SAP. During the early phase of the
disease, they developed pulmonary complications more













Figure 3 Dynamics of IAP with and without CVVH treatment. Significant difference on day 2 (p = 0.02).
Figure 4 Drop of IAP in CVVH group. Significant drop of IAP was seen in CVVH group comparing day 2 and day 7.
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of IAP, and it correlated with the achievement of negative
fluid balance. Our study was not aimed at analysis of the
particular mode of CVVH due to the fact that low substi-
tution rate was recommended by renal replacement ther-
apy specialists; however, application of low-flow
haemofiltration in patients with IAH is mentioned as an
optional strategy leading to promising results also by other
authors [14]. The mode of haemofiltration is a matter of
debate since not only the mechanical removal of cytokines
from the blood and reduction of tissue cytokine effects
could be important. Several authors argue against low-
flow CVVH, instead reporting promising experience with
high-flow haemofiltration [15,16]. However, the reported
series are small and lack adequate severity assessment.
Due to the retrospective design of the study, evaluation of
severity, systemic inflammatory response and organ failure
was based on assessment of routine clinical data, and this
certainly limits precise interpretation of the results. Never-
theless it is evident that CVVH was started in the risk
group even before the peak elevation of the CRP, giving
some ground for speculation that it could work in a pre-
ventive manner. Critical aspects of the procedure may be
invasiveness and increased infection risk. Analysis in all
patients and in patients with IAH did not demonstrate
increased complication risk associated with the procedure.
Moreover, application of CVVH resulted in a lower infec-
tion rate in patients with IAH and consequently in fewer
surgical interventions. This can be partially explained by
faster reduction of tissue compartments and exudate col-

















Figure 5 Dynamics of CRP in patients with IAH secondary to mode of treatment. Significant difference on day 3 (p = 0.05).
Table 4 Main outcomes
ICU stay, median days
(IQR)




All patients n = 130 9 (14 to 5.5) 20 (31 to 15) 12 (9.2%)
Influence of CVVH on outcome in whole group CVVH n = 75 12 (11 to 5) 20 (32 to 15) 8 (10.7%)
no CVVH n = 55 7 (16.5 to 6) 19 (27 to 15) 4 (7.3%)
p value NS NS NS
Influence of IAH on outcome in whole group IAH n = 89 10 (16 to 6) 32 (16 to 6) 11
(12.4%)
Normal IAP n = 41 6 (9 to 4) 16 (23.5 to 13) 1 (2.4%)
p value NS 0.05 0.044a
Influence of CVVH on outcome in patients with
IAH
CVVH N = 60 9 (16 to 6) 32 (60 to 12) 7 (11.7%)
No CVVH N = 29 10 (16 to 7.5) 24 (34 to 4) 4 (13.8%)
p value NS 0.05 NS
aFisher’s NS, likelihood significant.
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invasion or improving gut barrier function [17]. Although
reduction of the infection rate by prophylactic antibacterial
treatment is not proved, it was a constituent of our treat-
ment protocol and complies with recent recommendations
demonstrating benefits from broad-spectrum antibacterial
prophylaxis in cases of necrotizing pancreatitis proven by
CECT [18,19].
We provided outcome analysis in several aspects. Over-
all ICU stay, hospital stay and mortality rate were similar
in patients who underwent CVVH and who were treated
without CVVH, corresponding to internationally available
data favouring multidisciplinary approach and postponed
surgery [20]. IAH was associated with increased mortality
when we performed grouping of patients according to the
degree of IAP. Application of CVVH in patients with IAH
resulted in reduced hospital stay but did not significantly
change ICU stay or mortality. Univariate analysis revealed
that mortality is associated with surgical interventions and
longer ICU stay. Finally, the logistic regression analysis
revealed that renal dysfunction and pleural effusion are
independent predictors of IAH, but IAH is an independent
predictor of mortality. The predicting value of IAP
Table 5 Univariate analysis
Survivors N = 118 Non-survivors N = 12 p value
MODS, number of cases (%) 110 (93.2%) 11 (91.7%) NS
Necrotizing SAP, number of cases (%) 80 (67.8%) 10 (83.3%) NS
Surgery, number of cases (%) 42 (35.6%) 9 (75.0%) 0.01
ICU stay, median days (IQR) 8 (14 to 6) 11.5 (19.3 to 5) NS
Hospital stay, median days (IQR) 20 (31 to 15) 24 (33.5 to 16.3) NS
IAP on admission, mmHg 14.8 ± 4.2 16.4 ± 1.5 NS
Figure 6 ROC curve. Mortality predictive values of APP. The curve describes the association between sensitivity and specificity at different
thresholds of APP in predicting mortality. Cut-off values shown in the figure are 80.66 mmHg (true positive rate 57%, false positive rate 50%),
66.94 mmHg (true positive rate 85.1%, false positive rate 41.7%) and 62.26 mmHg (true positive rate 90.4%, false positive rate 33.3%). ROC curves
that approach the upper leftmost corner represent highly accurate studies - in this case, the area under the curve (AUC) is 0.548. Accuracy of
APP in predicting mortality has failed; also this ROC curve analysis is not significant - p value 0.583.
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according to ROC analysis was 14.8 mmHg. It means that
elevation of the IAP to this level could be a trigger for a
revision of the treatment strategy. Our results demonstrate
that application of CVVH can work preventively through
achievement of negative cumulative fluid balance and does
not increase complication rate, infection risk or mortality.
Our retrospective study has certain limitations due to
poor demographic data and relatively long time period
chosen for data analysis. The SOFA score was calculated
routinely for severity assessment, while APACHE II score
was calculated only on admission. However, during the
last 10 years, we have applied standardized conservative
treatment protocol, which allows us to suggest that the
overall treatment success can be evaluated with certain
precision. Changes in the IAP measurement technique
according to our data did not significantly influence
values of IAP measurements. We did not analyse a few
rare occasions when paracentesis or other nonsurgical
methods were used for control of the IAP because, if
these methods were successful, patients did not undergo
CVVH. Summarizing our 10 years of experience in the
clinical application of CVVH, we would recommend it as
a rational constituent of the conservative treatment pro-
tocol in patients with SAP who suffer from sustained
increase of the IAP.
Conclusions
Early application of CVVH facilitates negative fluid bal-
ance and reduction of IAH in patients with severe acute
pancreatitis; it is not associated with increased infection
or mortality rate and may reduce hospital stay.
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Figure 7 ROC curve. Mortality predictive values of IAP. The curve describes the association between sensitivity and specificity at different
thresholds of IAP in predicting mortality. Cut-off values shown in the figure are 15.13 mmHg (true positive rate 65%, false positive rate 68.3%),
17.09 mmHg (true positive rate 76.9%, false positive rate 50%) and 18.87 mmHg (true positive rate 82.9%, false positive rate 25%). ROC curves
that approach the upper leftmost corner represent highly accurate studies - in this case AUC is 0.703. Accuracy of IAP in predicting mortality is
fair, and ROC curve analyses is statistically significant - p value 0.021.
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